DB05082InvestigationalSmall molecule
ARX201 (PEG-ahGH) is a recombinant form of human growth hormone that has been modified using Ambrx’s patented ReCODE™ technology to achieve precise spatial positioning of the site of polyethylene glycol... ARX201 has improved pharmacological properties, which should allow less frequent administration than the daily dosing regimen of currently available growth hormones.
- Primary indication
- Investigated for use/treatment in growth hormone deficiencies/abnormalities.Curator reviewed
- Code names
- ARX201
What you can answer from here — as of April 02, 2025
Which companies are running trials of ARX201, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account